Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 17/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1925786 | 0.93 | S1PR1 (0.40) | GRM2S1PR1AAK1PDK2 | |
| SCHEMBL1924673 | 0.89 | S1PR1 (0.36) | GRM2S1PR1 | |
| SCHEMBL1924659 | 0.89 | GRM2 (0.44) | GRM2S1PR1 | |
| SCHEMBL1927217 | 0.87 | GRM2 (0.44) | GRM2S1PR1AAK1 | |
| SCHEMBL1924414 | 0.86 | GRM2 (0.51) | GRM2AAK1 | |
| SCHEMBL1924658 | 0.86 | PSEN1 (0.37) | GRM2S1PR1PDK2 | |
| SCHEMBL1924025 | 0.85 | TP53 (0.48) | GRM2PDK2 | |
| SCHEMBL1924522 | 0.85 | TP53 (0.44) | GRM2S1PR1PDK2 | |
| SCHEMBL1926736 | 0.84 | KMO (0.41) | GRM2 | |
| SCHEMBL1925499 | 0.84 | TP53 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670801-B1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-7514443-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors | HOFFMANN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080051421-A1 | Pyrazolo-pyridine | WICHMANN JUERGEN | 2008-02-28 | — | — | US | disclosed |
| US-7329662-B2 | Pyrazolo-pyridine | HOFFMANN-LA ROCHE INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050130992-A1 | Pyrazolo-pyridine | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130992-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | GRM2 219/4885S1PR1 967/4885AAK1 2024/4885 |
| US-20080051421-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | GRM2 219/4885S1PR1 967/4885AAK1 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.